Safety of belatacept bridging immunosuppression in hepatitis c-positive liver transplant recipients with renal dysfunction

John C. Lamattina, Mihaela P. Jason, Steven I. Hanish, Shane E. Ottmann, David K. Klassen, Darryn Potosky, William R. Hutson, Rolf N. Barth

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

BACKGROUND: Perioperative renal dysfunction in liver transplant recipients complicates maintenance immunosuppressive therapy, particularly in patients with hepatitis C. Calcineurin inhibitors exacerbate renal dysfunction and mammalian target-of-rapamycin inhibitors are generally avoided because of perceived perioperative risks. The authors' experience with seven liver transplant patients who received belatacept and mycophenolic acid maintenance immunosuppression is reported. METHODS: A retrospective review of adult liver transplant recipients with hepatitis C receiving belatacept was conducted under Institutional Review Board approval. All patients were Epstein-Barr virus IgG seropositive. The primary endpoint was patient and graft survival, with secondary endpoints including the incidence of acute rejection, degree of renal function recovery, and occurrence of major side effects. RESULTS: Between December 19, 2011 and January 25, 2013, seven liver transplant recipients with hepatitis C received belatacept immunosuppression in the perioperative period. The primary indication for belatacept was perioperative renal dysfunction. Belatacept was initiated between 2 and 90 days posttransplant and the duration of belatacept therapy ranged from 19 to 89 days. Patients were transitioned onto calcineurin inhibitor therapy when they reached chronic kidney disease stage 2 or better. Six-month patient and graft survival was 86%. There was one episode of graft rejection on belatacept therapy in a patient who had also had early rejection before initiation of belatacept. CONCLUSIONS: The results in this initial group of patients suggest that belatacept with mycophenolic acid may be a safe maintenance immunosuppression regimen in hepatitis C-positive liver transplant recipients with renal dysfunction, and that this regimen can serve as an effective bridge to calcineurin inhibitor therapy.

Original languageEnglish (US)
Pages (from-to)133-137
Number of pages5
JournalTransplantation
Volume97
Issue number2
DOIs
StatePublished - Jan 27 2014
Externally publishedYes

Fingerprint

Immunosuppression
Hepatitis
Kidney
Safety
Liver
Hepatitis C
Mycophenolic Acid
Maintenance
Graft Survival
Therapeutics
Transplant Recipients
Abatacept
Perioperative Period
Research Ethics Committees
Recovery of Function
Graft Rejection
Sirolimus
Immunosuppressive Agents
Human Herpesvirus 4
Chronic Renal Insufficiency

Keywords

  • Chronic kidney disease
  • Costimulatory blockade

ASJC Scopus subject areas

  • Transplantation

Cite this

Safety of belatacept bridging immunosuppression in hepatitis c-positive liver transplant recipients with renal dysfunction. / Lamattina, John C.; Jason, Mihaela P.; Hanish, Steven I.; Ottmann, Shane E.; Klassen, David K.; Potosky, Darryn; Hutson, William R.; Barth, Rolf N.

In: Transplantation, Vol. 97, No. 2, 27.01.2014, p. 133-137.

Research output: Contribution to journalArticle

Lamattina, John C. ; Jason, Mihaela P. ; Hanish, Steven I. ; Ottmann, Shane E. ; Klassen, David K. ; Potosky, Darryn ; Hutson, William R. ; Barth, Rolf N. / Safety of belatacept bridging immunosuppression in hepatitis c-positive liver transplant recipients with renal dysfunction. In: Transplantation. 2014 ; Vol. 97, No. 2. pp. 133-137.
@article{ca7e26d0268c4b9fb4c8676d98b2ab13,
title = "Safety of belatacept bridging immunosuppression in hepatitis c-positive liver transplant recipients with renal dysfunction",
abstract = "BACKGROUND: Perioperative renal dysfunction in liver transplant recipients complicates maintenance immunosuppressive therapy, particularly in patients with hepatitis C. Calcineurin inhibitors exacerbate renal dysfunction and mammalian target-of-rapamycin inhibitors are generally avoided because of perceived perioperative risks. The authors' experience with seven liver transplant patients who received belatacept and mycophenolic acid maintenance immunosuppression is reported. METHODS: A retrospective review of adult liver transplant recipients with hepatitis C receiving belatacept was conducted under Institutional Review Board approval. All patients were Epstein-Barr virus IgG seropositive. The primary endpoint was patient and graft survival, with secondary endpoints including the incidence of acute rejection, degree of renal function recovery, and occurrence of major side effects. RESULTS: Between December 19, 2011 and January 25, 2013, seven liver transplant recipients with hepatitis C received belatacept immunosuppression in the perioperative period. The primary indication for belatacept was perioperative renal dysfunction. Belatacept was initiated between 2 and 90 days posttransplant and the duration of belatacept therapy ranged from 19 to 89 days. Patients were transitioned onto calcineurin inhibitor therapy when they reached chronic kidney disease stage 2 or better. Six-month patient and graft survival was 86{\%}. There was one episode of graft rejection on belatacept therapy in a patient who had also had early rejection before initiation of belatacept. CONCLUSIONS: The results in this initial group of patients suggest that belatacept with mycophenolic acid may be a safe maintenance immunosuppression regimen in hepatitis C-positive liver transplant recipients with renal dysfunction, and that this regimen can serve as an effective bridge to calcineurin inhibitor therapy.",
keywords = "Chronic kidney disease, Costimulatory blockade",
author = "Lamattina, {John C.} and Jason, {Mihaela P.} and Hanish, {Steven I.} and Ottmann, {Shane E.} and Klassen, {David K.} and Darryn Potosky and Hutson, {William R.} and Barth, {Rolf N.}",
year = "2014",
month = "1",
day = "27",
doi = "10.1097/01.TP.0000438635.44461.2e",
language = "English (US)",
volume = "97",
pages = "133--137",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Safety of belatacept bridging immunosuppression in hepatitis c-positive liver transplant recipients with renal dysfunction

AU - Lamattina, John C.

AU - Jason, Mihaela P.

AU - Hanish, Steven I.

AU - Ottmann, Shane E.

AU - Klassen, David K.

AU - Potosky, Darryn

AU - Hutson, William R.

AU - Barth, Rolf N.

PY - 2014/1/27

Y1 - 2014/1/27

N2 - BACKGROUND: Perioperative renal dysfunction in liver transplant recipients complicates maintenance immunosuppressive therapy, particularly in patients with hepatitis C. Calcineurin inhibitors exacerbate renal dysfunction and mammalian target-of-rapamycin inhibitors are generally avoided because of perceived perioperative risks. The authors' experience with seven liver transplant patients who received belatacept and mycophenolic acid maintenance immunosuppression is reported. METHODS: A retrospective review of adult liver transplant recipients with hepatitis C receiving belatacept was conducted under Institutional Review Board approval. All patients were Epstein-Barr virus IgG seropositive. The primary endpoint was patient and graft survival, with secondary endpoints including the incidence of acute rejection, degree of renal function recovery, and occurrence of major side effects. RESULTS: Between December 19, 2011 and January 25, 2013, seven liver transplant recipients with hepatitis C received belatacept immunosuppression in the perioperative period. The primary indication for belatacept was perioperative renal dysfunction. Belatacept was initiated between 2 and 90 days posttransplant and the duration of belatacept therapy ranged from 19 to 89 days. Patients were transitioned onto calcineurin inhibitor therapy when they reached chronic kidney disease stage 2 or better. Six-month patient and graft survival was 86%. There was one episode of graft rejection on belatacept therapy in a patient who had also had early rejection before initiation of belatacept. CONCLUSIONS: The results in this initial group of patients suggest that belatacept with mycophenolic acid may be a safe maintenance immunosuppression regimen in hepatitis C-positive liver transplant recipients with renal dysfunction, and that this regimen can serve as an effective bridge to calcineurin inhibitor therapy.

AB - BACKGROUND: Perioperative renal dysfunction in liver transplant recipients complicates maintenance immunosuppressive therapy, particularly in patients with hepatitis C. Calcineurin inhibitors exacerbate renal dysfunction and mammalian target-of-rapamycin inhibitors are generally avoided because of perceived perioperative risks. The authors' experience with seven liver transplant patients who received belatacept and mycophenolic acid maintenance immunosuppression is reported. METHODS: A retrospective review of adult liver transplant recipients with hepatitis C receiving belatacept was conducted under Institutional Review Board approval. All patients were Epstein-Barr virus IgG seropositive. The primary endpoint was patient and graft survival, with secondary endpoints including the incidence of acute rejection, degree of renal function recovery, and occurrence of major side effects. RESULTS: Between December 19, 2011 and January 25, 2013, seven liver transplant recipients with hepatitis C received belatacept immunosuppression in the perioperative period. The primary indication for belatacept was perioperative renal dysfunction. Belatacept was initiated between 2 and 90 days posttransplant and the duration of belatacept therapy ranged from 19 to 89 days. Patients were transitioned onto calcineurin inhibitor therapy when they reached chronic kidney disease stage 2 or better. Six-month patient and graft survival was 86%. There was one episode of graft rejection on belatacept therapy in a patient who had also had early rejection before initiation of belatacept. CONCLUSIONS: The results in this initial group of patients suggest that belatacept with mycophenolic acid may be a safe maintenance immunosuppression regimen in hepatitis C-positive liver transplant recipients with renal dysfunction, and that this regimen can serve as an effective bridge to calcineurin inhibitor therapy.

KW - Chronic kidney disease

KW - Costimulatory blockade

UR - http://www.scopus.com/inward/record.url?scp=84895087271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895087271&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000438635.44461.2e

DO - 10.1097/01.TP.0000438635.44461.2e

M3 - Article

C2 - 24342980

AN - SCOPUS:84895087271

VL - 97

SP - 133

EP - 137

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -